| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 194.49K | 0 | 149.69K | 119.75K | 89.81K | 158.33K | 33K | 3.19M | 1.1M | 0 |
| Revenue Growth % | - | -1% | - | -0.2% | -0.25% | 0.76% | -0.79% | 95.61% | -0.66% | -1% |
| Cost of Goods Sold | 5.29M | 52.64K | 9.01M | 6.79M | 11.23M | 14.36M | 14.58M | 16.68M | 0 | 0 |
| COGS % of Revenue | 27.21% | - | 60.2% | 56.68% | 125.09% | 90.69% | 441.91% | 5.23% | - | - |
| Gross Profit | -5.1M | -52.64K | -8.86M | -6.67M | -11.14M | -14.2M | -14.55M | -13.49M | 1.1M | 0 |
| Gross Margin % | -26.21% | - | -59.2% | -55.68% | -124.09% | -89.69% | -440.91% | -4.23% | 1% | - |
| Gross Profit Growth % | 0.02% | 0.99% | -167.32% | 0.25% | -0.67% | -0.27% | -0.02% | 0.07% | 1.08% | -1% |
| Operating Expenses | 10.11M | 8.26M | 16.65M | 14.77M | 7.78M | 10.01M | 10.19M | 11.1M | 24.86M | 24.59M |
| OpEx % of Revenue | 51.96% | - | 111.25% | 123.31% | 86.58% | 63.2% | 308.64% | 3.48% | 22.68% | - |
| Selling, General & Admin | 4.81M | 4.31M | 7.64M | 7.98M | 7.78M | 10.01M | 10.19M | 11.1M | 10.37M | 8.73M |
| SG&A % of Revenue | 24.75% | - | 51.05% | 66.63% | 86.58% | 63.2% | 308.64% | 3.48% | 9.46% | - |
| Research & Development | 5.29M | 3.95M | 9.01M | 6.79M | 11.23M | 14.36M | 14.58M | 16.68M | 14.49M | 11.43M |
| R&D % of Revenue | 27.21% | - | 60.2% | 56.68% | 125.09% | 90.69% | 441.91% | 5.23% | 13.22% | - |
| Other Operating Expenses | 19.63K | -16.5K | 22.03K | 56.55K | -11.23M | -14.36M | -14.58M | -16.68M | 0 | 4.43M |
| Operating Income | -9.91M | -8.26M | -16.5M | -14.65M | -18.92M | -24.21M | -24.73M | -24.59M | -23.77M | -24.59M |
| Operating Margin % | -50.96% | - | -110.25% | -122.31% | -210.67% | -152.88% | -749.55% | -7.71% | -21.68% | - |
| Operating Income Growth % | 0.05% | 0.17% | -1% | 0.11% | -0.29% | -0.28% | -0.02% | 0.01% | 0.03% | -0.03% |
| EBITDA | -9.87M | -8.2M | -16.4M | -14.43M | -18.59M | -23.92M | -24.45M | -24.23M | -22.82M | -23.62M |
| EBITDA Margin % | -50.74% | - | -109.57% | -120.49% | -207.01% | -151.05% | -741.06% | -7.6% | -20.83% | - |
| EBITDA Growth % | 0.05% | 0.17% | -1% | 0.12% | -0.29% | -0.29% | -0.02% | 0.01% | 0.06% | -0.03% |
| D&A (Non-Cash Add-back) | 43.5K | 52.64K | 100.61K | 218.31K | 328.76K | 290.02K | 280K | 356K | 941K | 972K |
| EBIT | -9.91M | -8.26M | -16.5M | -14.65M | -18.92M | -24.21M | -24.73M | -24.59M | -23.77M | -20.16M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 776.1K | 658.4K | 658.96K | 56.55K | 1.55M | 1.76M | 1.45M | 3.59M | 824K | 262K |
| Pretax Income | -9.14M | -7.6M | -15.84M | -14.59M | -17.37M | -22.45M | -23.28M | -21M | -22.94M | -24.33M |
| Pretax Margin % | -46.97% | - | -105.84% | -121.84% | -193.43% | -141.77% | -705.55% | -6.59% | -20.93% | - |
| Income Tax | 0 | 0 | -356.96K | -506.92K | 0 | 0 | 0 | 0 | 0 | -80K |
| Effective Tax Rate % | 1% | 1% | 0.98% | 0.97% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -9.14M | -7.6M | -15.49M | -14.08M | -17.37M | -22.45M | -23.28M | -21M | -22.94M | -24.25M |
| Net Margin % | -46.97% | - | -103.46% | -117.6% | -193.43% | -141.77% | -705.55% | -6.59% | -20.93% | - |
| Net Income Growth % | 0.11% | 0.17% | -1.04% | 0.09% | -0.23% | -0.29% | -0.04% | 0.1% | -0.09% | -0.06% |
| Net Income (Continuing) | -9.14M | -7.6M | -15.49M | -14.08M | -17.37M | -22.45M | -23.28M | -21M | -22.94M | -24.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -8.87 | -6.59 | -8.56 | -7.18 | -5.37 | -5.23 | -5.04 | -3.00 | -5.28 | -4.98 |
| EPS Growth % | 0.44% | 0.26% | -0.3% | 0.16% | 0.25% | 0.03% | 0.04% | 0.4% | -0.76% | 0.06% |
| EPS (Basic) | -8.87 | -6.59 | -8.56 | -7.18 | -5.37 | -5.23 | -5.04 | -3.00 | -5.28 | -4.98 |
| Diluted Shares Outstanding | 1.03M | 1.15M | 1.81M | 1.96M | 2.9M | 3.94M | 4.2M | 4.34M | 4.35M | 4.87M |
| Basic Shares Outstanding | 1.03M | 1.15M | 1.81M | 1.96M | 2.9M | 3.94M | 4.2M | 4.34M | 4.35M | 4.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.56M | 4.57M | 7.96M | 13.09M | 29.92M | 61.55M | 50.99M | 34.53M | 15.54M | 8.03M |
| Cash & Short-Term Investments | 3.23M | 4.11M | 7.31M | 12.45M | 27.77M | 58.68M | 49.62M | 28.81M | 13.76M | 7.28M |
| Cash Only | 3.23M | 4.11M | 7.31M | 12.45M | 22.17M | 12.43M | 21.03M | 6.88M | 4.79M | 7.28M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 5.61M | 46.25M | 28.59M | 21.93M | 8.97M | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 100.33K | 155.61K | 155.43K | 100K | 250K | 136K | 49.53K | 5.72M | 50K | 741K |
| Total Non-Current Assets | 4.85M | 5.25M | 6.46M | 6.86M | 10.32M | 9.41M | 10.33M | 44.33M | 9.56M | 4.62M |
| Property, Plant & Equipment | 378K | 356K | 1.57M | 2.04M | 5.63M | 4.86M | 5.78M | 5.73M | 5.01M | 2.16M |
| Fixed Asset Turnover | 0.51x | - | 0.10x | 0.06x | 0.02x | 0.03x | 0.01x | 0.56x | 0.22x | - |
| Goodwill | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 0 |
| Intangible Assets | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 3.02M | 2.26M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200K | 0 | 200K |
| Other Non-Current Assets | 115.09K | 540.99K | 535.86K | 460.89K | 336K | 199.95K | 200K | 0 | 200K | 0 |
| Total Assets | 8.41M | 9.82M | 14.42M | 19.94M | 40.24M | 70.97M | 61.33M | 78.87M | 25.1M | 12.64M |
| Asset Turnover | 0.02x | - | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.04x | 0.04x | - |
| Asset Growth % | 1.5% | 0.17% | 0.47% | 0.38% | 1.02% | 0.76% | -0.14% | 0.29% | -0.68% | -0.5% |
| Total Current Liabilities | 1.13M | 1.44M | 2.22M | 2.84M | 3.1M | 3.57M | 4.35M | 4.29M | 2.62M | 2.67M |
| Accounts Payable | 497.84K | 475.6K | 582.87K | 295.65K | 679.31K | 349.94K | 937K | 618K | 514K | 95K |
| Days Payables Outstanding | 34.34 | 3.3K | 23.61 | 15.9 | 22.07 | 8.9 | 23.45 | 13.53 | - | - |
| Short-Term Debt | 0 | 118.05K | 170.24K | 199.84K | 0 | 0 | 0 | 569K | 0 | 0 |
| Deferred Revenue (Current) | 608.17K | 0 | 29.94K | -83.25K | 100K | 643K | 33K | 809K | 0 | 0 |
| Other Current Liabilities | 9.22K | 11.48K | 0 | 1.63M | 862K | 329 | 899K | 585K | 271K | 4K |
| Current Ratio | 3.15x | 3.16x | 3.58x | 4.61x | 9.66x | 17.25x | 11.73x | 8.06x | 5.93x | 3.01x |
| Quick Ratio | 3.15x | 3.16x | 3.58x | 4.61x | 9.66x | 17.25x | 11.73x | 8.06x | 5.93x | 3.01x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.21M | 1.22M | 1.52M | 961.63K | 4.09M | 3.67M | 4.48M | 37.94M | 3.24M | 2.38M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 3.75B | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 16.45K | 67.68K | 107.66K | 3.75M | 3.33M | 4.14M | 3.56M | 2.9M | 2.13M |
| Deferred Tax Liabilities | 1.21M | 1.21M | 848.18K | 341.26K | 341K | 341.26K | 341K | 34.39M | 341K | 257K |
| Other Non-Current Liabilities | 0 | 0 | 601.14K | 512.7K | -3.75B | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.33M | 2.67M | 3.74M | 3.8M | 7.19M | 7.24M | 8.83M | 42.23M | 5.86M | 5.05M |
| Total Debt | 11.26K | 144.43K | 264.89K | 390.74K | 4.23M | 3.75M | 4.7M | 4.12M | 3.56M | 2.89M |
| Net Debt | -3.22M | -3.96M | -7.04M | -12.06M | -17.94M | -8.68M | -16.33M | -2.76M | -1.23M | -4.39M |
| Debt / Equity | 0.00x | 0.02x | 0.02x | 0.02x | 0.13x | 0.06x | 0.09x | 0.11x | 0.18x | 0.38x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 6.07M | 7.15M | 10.68M | 16.14M | 33.05M | 63.73M | 52.49M | 36.64M | 19.25M | 7.59M |
| Equity Growth % | 1.73% | 0.18% | 0.49% | 0.51% | 1.05% | 0.93% | -0.18% | -0.3% | -0.47% | -0.61% |
| Book Value per Share | 5.90 | 6.20 | 5.90 | 8.23 | 11.38 | 16.18 | 12.49 | 8.45 | 4.43 | 1.56 |
| Total Shareholders' Equity | 6.07M | 7.15M | 10.68M | 16.14M | 33.05M | 63.73M | 52.49M | 36.64M | 19.25M | 7.59M |
| Common Stock | 5.72K | 5.82K | 9.34K | 11.33K | 16K | 20.01K | 22K | 22K | 22K | 1K |
| Retained Earnings | -23.19M | -35.18M | -51.27M | -65.94M | -84.38M | -107.51M | -131.63M | -152.63M | -175.57M | -199.82M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -439K | -1K | 228.17K | -145K | -824K | -221K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -7.81M | -6.12M | -11.46M | -10.32M | -14.09M | -17.37M | -15.22M | -19.16M | -15.28M | -15.88M |
| Operating CF Margin % | -40.18% | - | -76.56% | -86.19% | -156.91% | -109.69% | -461.3% | -6.01% | -13.94% | - |
| Operating CF Growth % | 0.02% | 0.22% | -0.87% | 0.1% | -0.37% | -0.23% | 0.12% | -0.26% | 0.2% | -0.04% |
| Net Income | -9.14M | -7.6M | -15.49M | -14.08M | -17.37M | -22.45M | -23.28M | -21M | -22.94M | -24.25M |
| Depreciation & Amortization | 43.5K | 52.64K | 100.61K | 218.31K | 780.82K | 774.59K | 781K | 898K | 941K | 972K |
| Stock-Based Compensation | 1.59M | 1.52M | 3.6M | 3.83M | 2.99M | 4.56M | 4.29M | 0 | 4.95M | 3.19M |
| Deferred Taxes | 0 | 0 | -356.96K | -506.92K | 6.42K | 8.48K | 0 | 0 | 0 | -84K |
| Other Non-Cash Items | 9.22K | 2.26K | 157.35K | 57.15K | 140 | 239.83K | 1.45M | 5.73M | 108K | 4.41M |
| Working Capital Changes | -324.1K | -93.79K | 528.57K | 160.24K | -492.07K | -508.69K | 1.53M | -4.79M | 1.67M | -131K |
| Change in Receivables | 45.64K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -73.73K | -22.24K | 107.27K | -287.21K | 383.66K | -329.37K | 588K | -321K | -103K | -419K |
| Cash from Investing | -5.42K | 0 | -942.18K | -535.92K | -6.01M | -40.67M | 16.77M | 4.88M | 13.24M | 9.21M |
| Capital Expenditures | -76.18K | 0 | -942.18K | -535.92K | -405.6K | -5.75K | -260K | -892K | -218K | 0 |
| CapEx % of Revenue | 0.39% | - | 6.29% | 4.48% | 4.52% | 0.04% | 7.88% | 0.28% | 0.2% | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -5.42M | 0 | -942.18M | -535.92M | -5.61M | -8.48M | 0 | 0 | 0 | 0 |
| Cash from Financing | 8.46M | 7M | 15.6M | 15.87M | 29.85M | 48.05M | 6.96M | 79K | -7K | 9.17M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | -4.39B | -608.34M | -587.14M | -2.23B | -682.8M | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 8.5M | 4.39B | 622.84M | 603.07M | 2.26B | 684.2M | 1.42M | 0 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -7.89M | -6.12M | -12.4M | -10.86M | -14.5M | -17.37M | -15.48M | -20.05M | -15.5M | -15.88M |
| FCF Margin % | -40.57% | - | -82.85% | -90.66% | -161.42% | -109.73% | -469.18% | -6.29% | -14.14% | - |
| FCF Growth % | 0.04% | 0.22% | -1.03% | 0.12% | -0.34% | -0.2% | 0.11% | -0.29% | 0.23% | -0.03% |
| FCF per Share | -7.66 | -5.31 | -6.85 | -5.53 | -4.99 | -4.41 | -3.68 | -4.62 | -3.57 | -3.26 |
| FCF Conversion (FCF/Net Income) | 0.86x | 0.81x | 0.74x | 0.73x | 0.81x | 0.77x | 0.65x | 0.91x | 0.67x | 0.66x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -220.12% | -114.94% | -173.69% | -105% | -70.63% | -46.39% | -40.07% | -47.11% | -82.11% | -180.73% |
| Return on Invested Capital (ROIC) | -582.23% | -204.87% | -362.46% | -284.36% | -147.85% | -51.75% | -40.68% | -52.66% | -68.69% | -173.88% |
| Gross Margin | -2621.01% | - | -5919.56% | -5568.04% | -12408.96% | -8968.81% | -44090.91% | -423.15% | 100% | - |
| Net Margin | -4697.01% | - | -10345.91% | -11760.4% | -19343.35% | -14176.98% | -70554.55% | -658.63% | -2093.25% | - |
| Debt / Equity | 0.00x | 0.02x | 0.02x | 0.02x | 0.13x | 0.06x | 0.09x | 0.11x | 0.18x | 0.38x |
| FCF Conversion | 0.86x | 0.81x | 0.74x | 0.73x | 0.81x | 0.77x | 0.65x | 0.91x | 0.67x | 0.66x |
| Revenue Growth | - | -100% | - | -20% | -25% | 76.29% | -79.16% | 9560.61% | -65.62% | -100% |
| 2020 | |
|---|---|
| CFF Research Grant Revenue | 125K |
| CFF Research Grant Revenue Growth | - |
Matinas BioPharma Holdings, Inc. (MTNB) saw revenue decline by 100.0% over the past year.
Matinas BioPharma Holdings, Inc. (MTNB) reported a net loss of $17.5M for fiscal year 2024.
Matinas BioPharma Holdings, Inc. (MTNB) has a return on equity (ROE) of -180.7%. Negative ROE indicates the company is unprofitable.
Matinas BioPharma Holdings, Inc. (MTNB) had negative free cash flow of $9.0M in fiscal year 2024, likely due to heavy capital investments.